OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Fatty liver and cerebrovascular disease: plausible association and possible mechanisms	49
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	49
Cholesterol in older age – it matters to mind	48
Editorial introductions	45
Editorial introduction	34
Updates on genetics and molecular biology	33
Brain lipid metabolism: the emerging role of lipid droplets in glial cells	32
Editorial introductions	29
Editorial introduction	28
Editorial introduction	28
Role of VLDL receptor in atherogenesis	26
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	25
What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline myths	24
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies	24
Ketogenic therapies in mild cognitive impairment and dementia	24
Early atherogenesis: new insights from new approaches	23
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	23
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	22
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm	21
ANGPTL4: a new mode in the regulation of intravascular lipolysis	20
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	17
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	16
Cardiomyocytes, sphingolipids and cardio myotoxicity	15
Newborn screening for lipid disorders	15
Sphingomyelins and ceramides: possible biomarkers for dementia?	14

Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	14
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	13
How should low-density lipoprotein cholesterol be calculated in 2022?	13
Dietary factors and brain health	13
Familial combined hyperlipidemia is a polygenic trait	12
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	12
Very long-chain saturated fatty acids and diabetes and cardiovascular disease	12
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction	11
Links between ceramides and cardiac function	11
Editorial introduction	11
Omega-3 fatty acids and cognitive function	11
Editorial introductions	11
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis	11
Editorial introductions	11
The power of lipid registries for cardiovascular disease prevention	10
Update on proprotein convertase subtilisin/kexin type 9 inhibitors, lipoprotein(a) and cardiovascular risk	10
Preprint servers in lipidology: current status and future role	10
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	9
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	9
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	9
Clinical associations between exercise and lipoproteins	9
The clinical utility of polygenic risk scores for combined hyperlipidemia	9
Altered cardiovascular risk pattern of LDL cholesterol in older adults	9
LDL receptor-related protein 1 and its interacting partners in tissue homeostasis	9
Diagnosis of remnant hyperlipidaemia	8
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	7
Cardiovascular disease prevention in heterozygous familial hypercholesterolemia: how important is a healthy diet in the era of long-lasting cholesterol-lowering drug therapies?	7
The iterative lipid impact on inflammation in atherosclerosis	7
Strategies for management of patients with elevated lipoprotein(a)	7
Angiopoietin-like proteins and postprandial partitioning of fatty acids	7
Lipidome and inflammation interplay: the role of diet in this relationship	7
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	7
Pregnancy, cardiovascular health, and microchimerism	7
Implementation science and genetic testing for familial hypercholesterolemia	7
Preeclampsia and fetal growth restriction: does novel proteomics reveal immunological possible candidate biomarkers?	7
Genetic testing for familial hypercholesterolemia	6
Sweet swell of burning fat: emerging role of high-density lipoprotein in energy homeostasis	6
C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden	6
Oxidized LDL receptors: a recent update	6
Altered lipid metabolism and the development of metabolic-associated fatty liver disease	6
Predictors of cardiovascular risk in familial hypercholesterolemia	6
Metabolic regulation of macrophage proliferation and function in atherosclerosis	5
Understanding the ins and outs of lipoprotein (a) metabolism	5
Familial hypercholesterolemia in children and the importance of early treatment	5
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	5
Emerging agents targeting triglycerides	5
Lipids and cardiovascular calcification: contributions to plaque vulnerability	5
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	4
Genetic influences on macrophage function and lipid uptake in atherosclerosis	4
Lipid metabolism during pregnancy: consequences for mother and child	4

Quantification of high-density lipoprotein particle number by proton nuclear magnetic resonance: don’t believe the numbers	4
New algorithms for treating homozygous familial hypercholesterolemia	4
Angiopoietin-like 3 inhibition and the liver: less is more?	4
Management of familial hypercholesterolemia in pregnancy	4
Polygenic risk scores: how much do they add?	4
Current models of apolipoprotein A-I lipidation by adenosine triphosphate binding cassette transporter A1	3
Editorial introduction	3
Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies	3
Cholesterol 25-hydroxylase expression following immune activation in response to SARS-CoV-2 infection	3
Soy consumption, cognitive function, and dementia	3
Nonalcoholic fatty liver disease: an update	3
Pancreatic and cardiometabolic complications of severe hypertriglyceridaemia	3
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	3
From unbiased transcriptomics to understanding the molecular basis of atherosclerosis	3
Regulation of cardiovascular calcification by lipids and lipoproteins	3
Genetic variants associated with cardiovascular diseases and related risk factors highlight novel potential therapeutic approaches	3
Combination lipid therapy: could teamwork make the dream work?	3
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications	2
Novel functions of Tribbles-homolog 1 in liver, adipocytes and atherosclerosis	2
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	2
Lymphatics - not just a chylomicron conduit	2
Editorial introductions	2
Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?	2
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	2
Intracellular lipase and regulation of the lipid droplet	2
HDL and persistent inflammation immunosuppression and catabolism syndrome	2
Evolving ANGPTL-based lipid-lowering strategies and beyond	2
Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease	2
Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides	2
The pathophysiology of excess plasma-free cholesterol	2
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	2
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	2
DNA testing in dyslipidemia: attitudes and complexities	2
Prevention of cardiometabolic diseases through dietary modifications	2